Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Bruce Trusock

Neuromusculoskeletal Medicine, Sports Medicine Houghton, MI Medical Doctor

NPI 1003876533 CMS profile 45466

600 MacInnes Dr., Houghton, MI 49930

Open in the dashboard

General payments

$229

23 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Bruce Trusock of Houghton, MI is reported in the CMS Open Payments database as having received $229 across 23 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 50th percentile of Neuromusculoskeletal Medicine, Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $25 2
2019 General $204 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bruce Trusock
  • Neuromusculoskeletal Medicine, Sports Medicine median
  • Middle half of Neuromusculoskeletal Medicine, Sports Medicine
  • National median

In program year 2025, general payments to Bruce Trusock were reported at $0. Among 69 Neuromusculoskeletal Medicine, Sports Medicine profiles paid that year, the median was $125 and the middle half received between $37 and $473.

Show as a table
Year Bruce Trusock Neuromusculoskeletal Medicine, Sports Medicine median Middle half National median
2019 $204 $152 $43–$474 $163
2020 $25 $113 $31–$725 $114
2021 $0 $167 $50–$469 $132
2022 $0 $132 $46–$572 $149
2023 $0 $109 $39–$366 $160
2024 $0 $115 $37–$321 $164
2025 $0 $125 $37–$473 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Sunovion Pharmaceuticals Inc. $100 13 payments
  2. Pfizer Inc. $27 2 payments
  3. Lilly USA, LLC $27 2 payments
  4. Merck Sharp & Dohme Corporation $23 2 payments
  5. Janssen Pharmaceuticals, Inc $23 2 payments
  6. Biogen, Inc. $16 1 payment
  7. GlaxoSmithKline, LLC. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $229 23 payments
Products named General payments · program years 2019–2020
  1. LONHALA MAGNAIR $100 13 payments
  2. EUCRISA $27 2 payments
  3. COLOGUARD $27 2 payments
  4. EMGALITY $27 2 payments
  5. XARELTO $23 2 payments
  6. INVOKANA $23 2 payments
  7. SPINRAZA $16 1 payment
  8. CHANTIX Neuroscience;Tobacco Dependence $14 1 payment
  9. CHANTIX Neuroscience;Tobacco Dependence $13 1 payment
  10. GARDASIL 9 $12 1 payment
  11. Other $71 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 85 drugs

Part D claims

4,195

Median for Family Practice: 1,826

Drug cost

$356,952

Median for Family Practice: $120,094

Branded share of claims

20.4%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 144 $110,761
Ozempic Semaglutide Brand 48 $54,065
Xarelto Rivaroxaban Brand 67 $43,571
Januvia Sitagliptin Phosphate Brand 22 $30,051
Jardiance Empagliflozin Brand 19 $21,327
Breo Ellipta Fluticasone/Vilanterol Brand 26 $11,631
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 13 $10,079
Rosuvastatin Calcium Generic 192 $4,948
Atorvastatin Calcium Generic 170 $3,029
Fentanyl Generic 41 $2,999

The 10 drugs with the highest cost, of 85 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$490

Medicare's payments for the services billed

Medicare patients

12

Average age 74

Services billed

17

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Osteoporosis 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

23 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neuromusculoskeletal Medicine, Sports Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record